A future of global impact — built on more than four decades of one of the world's most accomplished records in antibiotic discovery.
In Canada's history, only two home-discovered antibiotics have ever reached the global market. Fedora's team discovered both.
Fedora Pharmaceuticals Inc. is a Canadian biotechnology company dedicated to discovering and developing first-in-class antibacterial therapies to combat the growing global threat of antimicrobial resistance. The first Canadian antibiotic to reach the world was tazobactam, invented by the late Dr. Ronald Micetich; the second was nacubactam, discovered by Fedora under the leadership of Christopher Micetich — cementing the Micetich family's extraordinary record of translating science into life-saving medicines.
Dr. Ronald Micetich invents tazobactam, one of the world's most widely used β-lactamase inhibitors — and one of only two Canadian-discovered antibiotics ever to reach the global marketplace. It still restores the effectiveness of antibiotics against resistant bacteria today.
Dr. Ronald G. Micetich co-founds SynPhar Laboratories, a pioneering Canadian–Japanese joint venture — the foundation of a family legacy in antibiotic research.
Ronald and Christopher Micetich co-found NAEJA Pharmaceutical, growing it into one of North America's premier drug discovery organizations and a home for a world-class team of chemists, microbiologists, and pharmacologists.
Following Dr. Ronald Micetich's passing, Christopher Micetich leads NAEJA through a period of exceptional growth — expanding to more than 160 employees, including the largest concentration of Ph.D. medicinal chemists in Canada.
Dr. Ronald Micetich is posthumously inducted into the BioAlberta BioIndustry Hall of Fame in recognition of his pioneering contributions to medicinal chemistry and antibiotic discovery.
Christopher Micetich founds Fedora Pharmaceuticals with a singular mission: to overcome antimicrobial resistance. The team discovers nacubactam, a novel β-lactam enhancer with a unique dual mechanism — combining β-lactamase inhibition with direct antibacterial activity.
Nacubactam is licensed to Hoffmann-La Roche in an agreement valued at up to US$750 million — one of the largest biotechnology licensing transactions ever completed by a Canadian anti-infective company.
Christopher Micetich is inducted into the BioAlberta BioIndustry Hall of Fame for his leadership and lasting contributions to Alberta's biotechnology industry and Canada's life sciences sector.
Fedora advances FPI-2119, a first-in-class, non-β-lactam penicillin-binding protein inhibitor derived from the lactivicin family — designed against the multidrug-resistant Gram-negative pathogens named as critical threats by the WHO, CDC, and Canadian public health authorities.
From tazobactam to nacubactam, and now FPI-2119, Fedora represents a continuous legacy of antibiotic innovation spanning more than four decades. Few organizations in the world possess a comparable record of discovering antibiotics that successfully progress from the laboratory to patients around the globe.
Today, Fedora remains committed to discovering the next generation of life-saving antibacterial therapies, forging international partnerships, and delivering medicines that address the urgent and evolving challenge of antimicrobial resistance.
